{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:02:40Z","timestamp":1756339360316,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>New contraindication for\u00a0\u25bcmirabegron \u25cf Naloxone: new regulations for emergency use \u25cf OTC analgesics for acute pain\u00a0\u25cf Interventions have lasting effect on preventing or delaying diabetes \u25cf EMA: no causal link between HPV vaccine and CRPS or POTS \u25cf Pharmaceutical care interventions for medication underuse in older people \u25cf New EMA guidelines for post-authorisation efficacy studies \u25cf WHO\/UNAIDS standards for improving adolescent care \u25cf Preventing seasonal affective disorder<\/jats:p>","DOI":"10.1136\/dtb.2016.1.0374","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T20:09:02Z","timestamp":1451938142000},"page":"2-5","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["DTB Select: 1 | January 2016"],"prefix":"10.1136","volume":"54","member":"239","published-online":{"date-parts":[[2016,1,3]]},"reference":[{"issue":"(3)","key":"2025082700150015000_54.1.2.1","first-page":"1","article-title":"Mirabegron (Betmiga\u25bc): risk of severe hypertension and associated cerebrovascular and\u00a0cardiac events","volume":"9","author":"Medicines and Healthcare products Regulatory Agency","year":"2015","journal-title":"Drug Safety Update"},{"key":"2025082700150015000_54.1.2.2","unstructured":"Betmiga 25mg & 50mg prolonged-release tablets. Summary of product characteristics, EU. Astellas Pharma Europe B.V., September 2015."},{"key":"2025082700150015000_54.1.2.3","doi-asserted-by":"crossref","unstructured":"\u25bcMirabegron for overactive bladder syndrome. DTB 2013; 51: 90\u20132.","DOI":"10.1136\/dtb.2013.8.0196"},{"key":"2025082700150015000_54.1.2.4","unstructured":"European Medicines Agency, 2012. Assessment report: Betmiga [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002388\/WC500137308.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.5","unstructured":"Department of Health, Medicines and Healthcare products Regulatory Agency, Public\u00a0Health England, 2015. Widening the availability of naloxone [online]. Available: https:\/\/www.gov.uk\/government\/publications\/widening-the-availability-of-naloxone [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.6","unstructured":"Public Health England, 2015. Take-home naloxone for opioid overdose in people who use drugs [online]. Available: http:\/\/www.nta.nhs.uk\/uploads\/phetake-homenaloxoneforopioidoverdosefeb2015rev.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.7","unstructured":"Public Health England, 2015. Naloxone\u2014preliminary advice from the working group updating drug misuse and dependence: UK guidelines on clinical management [online]. Available: http:\/\/www.nta.nhs.uk\/uploads\/chairsletter-naloxone-22july2015.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.8","unstructured":"Department of Health (England) and the devolved administrations, 2007. Drug misuse and dependence: UK guidelines on clinical management [online]. Available: http:\/\/www.nta.nhs.uk\/uploads\/clinical_guidelines_2007.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.9","first-page":"CD010794","article-title":"Non-prescription (OTC) oral analgesics for acute pain\u2014an overview of Cochrane reviews","volume":"11","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082700150015000_54.1.2.10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00291-0"},{"key":"2025082700150015000_54.1.2.11","doi-asserted-by":"crossref","unstructured":"Knowler WC , et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393\u2013403.","DOI":"10.1056\/NEJMoa012512"},{"key":"2025082700150015000_54.1.2.12","unstructured":"European Medicines Agency, 2015. Review concludes evidence does not support that HPV vaccines cause CRPS or POTS [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/11\/news_detail_002429.jsp&mid=WC0b01ac058004d5c1 [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.13","unstructured":"European Medicines Agency, 2015. EMA to further clarify safety profile of human papillomavirus (HPV) vaccines [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2015\/07\/WC500189481.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.14","doi-asserted-by":"crossref","unstructured":"Meid AD , et al . The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and meta-analysis. Br J Clin Pharmacol 2015; 80: 768\u201376.","DOI":"10.1111\/bcp.12657"},{"key":"2025082700150015000_54.1.2.15","unstructured":"European Medicines Agency, 2015. Scientific guidance on post-authorisation efficacy studies [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/11\/WC500196379.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.16","unstructured":"European Union, 2014. Commission delegated regulation (EU) no 357\/2014 [online]. Available: http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/reg_2014_357\/reg_2014_357_en.pdf [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.17","unstructured":"World Health Organization, 2015. Global standards for quality health care services for adolescents [online]. Available: http:\/\/www.who.int\/maternal_child_adolescent\/documents\/global-standards-adolescent-care\/en\/ [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.18","doi-asserted-by":"crossref","unstructured":"Nair M , et al . Improving the quality of health care services for adolescents, globally: a\u2005standards-driven approach. J Adolesc Health 2015; 57: 288\u201398.","DOI":"10.1016\/j.jadohealth.2015.05.011"},{"key":"2025082700150015000_54.1.2.19","unstructured":"World Health Organization, 2014. WHO calls for stronger focus on adolescent health [online]. Available: http:\/\/www.who.int\/mediacentre\/news\/releases\/2014\/focus-adolescent-health\/en\/ [Accessed 16 December 2015]."},{"key":"2025082700150015000_54.1.2.20","first-page":"CD011268","article-title":"Second-generation antidepressants for preventing seasonal affective disorder in adults","volume":"11","author":"Gartlehner","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082700150015000_54.1.2.21","first-page":"CD011269","article-title":"Light therapy for preventing seasonal affective disorder","volume":"11","author":"Nussbaumer","year":"2015","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2016.1.0374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:15:22Z","timestamp":1756278922000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2016.1.0374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,13]]},"published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1136\/dtb.2016.1.0374"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2016.1.0374","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}